In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are non-susceptible to fluconazole

This publication has 16 references indexed in Scilit:

• In Vitro Susceptibilities of Candida Bloodstream Isolates to the New Triazole Antifungal Agents BMS-207147, Sch 56592, and Voriconazole
  Antimicrobial Agents and Chemotherapy, 1998
• In Vitro Activity of a New Oral Triazole, BMS-207147 (ER-30346)
  Antimicrobial Agents and Chemotherapy, 1998
• Clinically significant azole cross-resistance in Candida isolates from HIV-positive patients with oral candidosis
  AIDS, 1997
• Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene
  Microbiology, 1997
• Detection and Significance of Fluconazole Resistance in Oropharyngeal Candidiasis in Human Immunodeficiency Virus-Infected Patients
  The Journal of Infectious Diseases, 1996
• Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility
  Antimicrobial Agents and Chemotherapy, 1995
• Emergence of azole drug resistance in Candida species from HIV-infected patients receivingprolonged fluconazole therapy for oral candidosis
  Journal of Antimicrobial Chemotherapy, 1995
• High prevalence of antifungal resistance in Candida spp. from patients with AIDS
  Journal of Antimicrobial Chemotherapy, 1994
• Resistance of Candida albicans to Fluconazole During Treatment of Oropharyngeal Candidiasis in a Patient with AIDS: Documentation by In Vitro Susceptibility Testing and DNA Subtype Analysis
  Clinical Infectious Diseases, 1994
• A comparison of the sterol content of multiple isolates of the Candida albicans Darlington strain with other clinically azole‐sensitive and ‐resistant strains
  Journal of Applied Bacteriology, 1990